Chris Shibutani
Showing 1–2 of 2 transcripts.
- Goldman Sachs10 min
Biopharma opportunities and macro challenges: A check-up on the industry
Asad Haider, Chris Shibutani, Salveen Richter, Sylvain
Major pharmaceutical and biotech leaders converged to identify GLP-1 agonists and AI integration as primary drivers for a market revised upward to $130 billion, while strategically addressing patent cliffs through aggressive external collaborations and M&A targeting metabolic and neurology assets. Although the biotech IPO window has reopened with nine clinical-stage offerings, investor sentiment remains sensitive to interest rate trajectories and the need for immediate commercial validation of AI-driven discoveries. Consequently, industry capital allocation prioritizes balancing near-term revenue generators with long-term growth catalysts to navigate complex clinical challenges in the central nervous system and cardiovascular disease sectors.
- Goldman Sachs11 min
Biotech and the Transition from Pandemic to Endemic
The event analyzes the global transition toward an endemic phase for COVID-19, highlighting a significant disparity where Western nations with high immunization rates differ from the majority of countries in Africa, Asia, and Latin America that remain in the pandemic stage. Industry leaders at BioNTech, Pfizer, and Moderna are currently developing multivalent mRNA vaccines to merge seasonal flu and coronavirus protection, shifting strategies toward frequent boosters to manage waning immunity. The discussion underscores the unprecedented speed of regulatory transparency and clinical development achieved last year while warning against complacency as the world prepares for future pandemic threats.